Lexington biotech Agenus to cut 50 jobs in reorganization
Lexington-based Agenus Inc. announced plans to phase out 50 jobs worldwide over the next six months — about 20 percent of its headcount — and close a facility in Switzerland as it reorganizes to focus on two potential cancer treatments and its vaccine in development.
Agenus (Nasdaq: AGEN) said it plans to “consolidate key functions to its Cambridge, UK and Lexington, MA facilities,” and t hat Robert Stein, now president of research and development, will retire to become a senior R&D advisor …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Jobs | Pharmaceuticals | Vaccines